Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Fidaxomicin in preparation of medicines treating related diseases and/or symptoms caused by Zika virus infection

A technology for Zika virus and fidaxomicin, which is applied in the field of medicine, can solve the problems of lack of effective drugs, etc., and achieve the effect of inhibiting Zika virus with high activity, high safety and strong binding ability

Active Publication Date: 2018-02-27
SUN YAT SEN UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is a lack of clinically approved effective drugs against Zika virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Fidaxomicin in preparation of medicines treating related diseases and/or symptoms caused by Zika virus infection
  • Application of Fidaxomicin in preparation of medicines treating related diseases and/or symptoms caused by Zika virus infection
  • Application of Fidaxomicin in preparation of medicines treating related diseases and/or symptoms caused by Zika virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: Fidaxomicin inhibits ZIKV activity at the cellular level

[0023] Virus strain: Zika virus ZIKV (Z16019)

[0024] Cell line: A549

[0025] Detection method:

[0026] Fidaxomycin antiviral half effective dose (50% Effective Concentration, EC 50 ): DMSO, 6, 9, 12, 18, 24 μM Fidaxomycin saturated cells 1 hour in advance, 2 hours after virus infection, changed to virus-free medium containing corresponding concentration of drugs for 48 hours; collected cell supernatant, detected by plaque test Plaque formation inhibition rate of different doses of fidaxomicin group relative to solvent group (DMSO) after virus infection.

[0027] Inhibition rate (%) = (1-the number of virus plaques in the administration group / the number of plaques in the solvent control group) 100%, calculated using the Forcast formula of EXCEL2013, when the inhibition rate is equal to 50%, the corresponding fidaxomicin Concentration, as EC 50 . The average value was obtained from three repea...

Embodiment 2

[0031] Example 2 The inhibitory activity of fidaxomicin to ZIKV-NS3 protein in A549 cell line

[0032] Virus strain: Zika virus ZIKV (Z16019)

[0033] Cell line: A549

[0034] Detection method:

[0035] DMSO, 10, 50, 100 μM Fidaxomycin saturated the cells 1 hour in advance, and 2 hours after the virus infection, the virus-free medium containing the corresponding concentration of drugs was maintained for 48 hours; the cell pellet was collected, and Western blot electrophoresis was used to detect ZIKV in the cells under different treatments -The relative expression level of NS3 protein, using GAPDH as an internal reference protein. like figure 1 As shown, fidaxomicin can effectively inhibit the expression of ZIKV NS3 protein at 10-50 μM, thereby preventing the reproduction of ZIKV.

Embodiment 3

[0036] Example 3 Anti-ZIKV activity of Fidaxomycin in mice

[0037] Mouse strain: C57BL / 6J WT

[0038] Model: anti-IFNAR1 antibody blocking method

[0039] Experimental method: 5~6W mice were intraperitoneally injected with antibodies one day in advance, and intraperitoneally infected with ZIKV 1×10 5 PFU virus was administered intraperitoneally after 4 hours, and Mock group, solvent control group, and fidaxomicin dose groups of 30, 75, and 150 mg / kg were set up, and the administration was continued for 7 days. On the 8th day, the mice were killed and the spleen was dissected for qRT-PCR Methods The copy number of ZIKV virus RNA in the spleen was detected. The result is as figure 2 , in mice, the doses of 75mg / kg and 150mg / kg have obvious anti-ZIKV effect (p<0.01). Correspondingly, there was no death in the dose of 150 mg / kg for 7 consecutive days, and no obvious toxic and side effects in the dose of 75 mg / kg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of Fidaxomicin in preparation of medicines treating related diseases and / or symptoms caused by Zika virus infection. Fidaxomicin is approved in clinic to serve as amedicine resisting clostridium difficile infection, is highly safe, has high activity in inhibiting Zika virus, and can relatively strongly bond with non-structural protein NS5 of the Zika virus, thereby being expected to be a new, effective medicine resisting Zika virus infection.

Description

technical field [0001] The invention belongs to the field of medicine, and more specifically relates to the application of fidaxomicin in the preparation of medicines for treating related diseases and / or symptoms caused by Zika virus infection. Background technique [0002] Fidaxomicin (trade name Dificid, also known as difimicin, lipiarmycin, tiacumicin B, formerly used names: PAR-101, OPT-80) is a bacterial DNA-dependent RNase inhibitor. Developed by Optimer for the initial treatment of Clostridium difficile infection (CDI) and the prevention of CDI recurrence, in January 2011, the US Food and Drug Administration (FDA) passed the approval of Fidaxomicin for the treatment of pediatric CDI Eligibility Application, In May 2011, the FDA approved fidaxomicin for the treatment of CDI in adults. [0003] The structure of Fidaxomycin is as follows: . [0004] Zika virus belongs to the Flavivirus genus of the Flaviviridae family. It is an RNA positive-strand virus that is trans...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P31/14
CPCA61K31/7048Y02A50/30
Inventor 黎孟枫袁洁朱勋于暕辰
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com